[{"orgOrder":0,"company":"ExCellThera","sponsor":"IRICoR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"ExCellThera \/ IRICoR"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Paradox Immunotherapeutics","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"LX-96","moa":"Diseased IgG light chain","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Paradox Immunotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Paradox Immunotherapeutics \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"4","companyTruncated":"Paradox Immunotherapeutics \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Oak Bay Biosciences","sponsor":"FrontFundr","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Complement pathway","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oak Bay Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oak Bay Biosciences \/ FrontFundr","highestDevelopmentStatusID":"4","companyTruncated":"Oak Bay Biosciences \/ FrontFundr"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The financing will be used to advance Paradox’s therapeutic pipeline, which includes LX-96, a monoclonal antibody designed for the treatment of late-stage immunoglobulin light chain (AL) amyloidosis.

                          Product Name : LX-96

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          February 25, 2025

                          Lead Product(s) : LX-96

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Symbiosis Pharmaceutical Services

                          Deal Size : $10.0 million

                          Deal Type : Financing

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The pioneering Phase II clinical trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with Fragile X syndrome.

                          Product Name : NM-1001

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          November 17, 2022

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Nova Mentis Life Science

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : With no treatments currently available, Oak Bay Biosciences ‘Lead Molecule’ could be more than 90% effective in preventing the retinal cell death associated with Stargardt disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 29, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : FrontFundr

                          Deal Size : $1.0 million

                          Deal Type : Funding

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Nova Mentis has filed a genetic neuroinflammatory disease patent which describes a diagnostic/therapeutic combination of mRNA molecules that encode proteins involved in the development of neurogenerative diseases, including fragile X syndrome and autism ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 11, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Proceeds will be used to develop Inversago’s best-in-class peripherally-acting CB1 inverse agonist candidate INV-101 to clinical proof-of-concept, and advance the research on other selected compounds.

                          Product Name : INV-101

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          August 09, 2020

                          Lead Product(s) : INV-101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Forbion

                          Deal Size : $35.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickl...

                          Product Name : ECT-001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 08, 2020

                          Lead Product(s) : ECT-001

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : IRICoR

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank